IGF2 and colorectal carcinoma: Other current studies apply IGF2 in a panel with other CRC-specific markers (e.g., CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) to study the CpG island methylator phenotype (CIMP) phenotype in primary and metastatic CRC [25,70,160].